At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Videos|February 15, 2021
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
Advertisement
Advertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
5